278 related articles for article (PubMed ID: 19759417)
1. Different angiogenic potential in low and high grade sporadic clear cell renal cell carcinoma is not related to alterations in the von Hippel-Lindau gene.
Baldewijns MM; van Vlodrop IJ; Smits KM; Vermeulen PB; Van den Eynden GG; Schot F; Roskams T; van Poppel H; van Engeland M; de Bruïne AP
Cell Oncol; 2009; 31(5):371-82. PubMed ID: 19759417
[TBL] [Abstract][Full Text] [Related]
2. [The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].
Gong K; Zhang N; Na X; Wu G; Yang XY; Xin DQ; Na YQ
Zhonghua Wai Ke Za Zhi; 2005 Mar; 43(6):390-3. PubMed ID: 15854350
[TBL] [Abstract][Full Text] [Related]
3. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
Damjanovic SS; Ilic BB; Beleslin Cokic BB; Antic JA; Bankovic JZ; Milicevic IT; Rodic GS; Ilic DS; Todorovic VN; Puskas N; Tulic CD
Exp Mol Pathol; 2016 Dec; 101(3):323-331. PubMed ID: 27845047
[TBL] [Abstract][Full Text] [Related]
4. Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.
Moore LE; Nickerson ML; Brennan P; Toro JR; Jaeger E; Rinsky J; Han SS; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Schmidt LS; Lenz P; Karami S; Linehan WM; Merino M; Chanock S; Boffetta P; Chow WH; Waldman FM; Rothman N
PLoS Genet; 2011 Oct; 7(10):e1002312. PubMed ID: 22022277
[TBL] [Abstract][Full Text] [Related]
5. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
[TBL] [Abstract][Full Text] [Related]
6. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
Gong K; Zhang N; Zhang K; Na Y
Int J Mol Med; 2010 Dec; 26(6):907-12. PubMed ID: 21042786
[TBL] [Abstract][Full Text] [Related]
7. Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma.
Patard JJ; Rioux-Leclercq N; Masson D; Zerrouki S; Jouan F; Collet N; Dubourg C; Lobel B; Denis M; Fergelot P
Br J Cancer; 2009 Oct; 101(8):1417-24. PubMed ID: 19755989
[TBL] [Abstract][Full Text] [Related]
8. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
[TBL] [Abstract][Full Text] [Related]
9. Renal Cell Carcinoma Programmed Death-ligand 1, a New Direct Target of Hypoxia-inducible Factor-2 Alpha, is Regulated by von Hippel-Lindau Gene Mutation Status.
Messai Y; Gad S; Noman MZ; Le Teuff G; Couve S; Janji B; Kammerer SF; Rioux-Leclerc N; Hasmim M; Ferlicot S; Baud V; Mejean A; Mole DR; Richard S; Eggermont AM; Albiges L; Mami-Chouaib F; Escudier B; Chouaib S
Eur Urol; 2016 Oct; 70(4):623-632. PubMed ID: 26707870
[TBL] [Abstract][Full Text] [Related]
10. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors.
Nickerson ML; Jaeger E; Shi Y; Durocher JA; Mahurkar S; Zaridze D; Matveev V; Janout V; Kollarova H; Bencko V; Navratilova M; Szeszenia-Dabrowska N; Mates D; Mukeria A; Holcatova I; Schmidt LS; Toro JR; Karami S; Hung R; Gerard GF; Linehan WM; Merino M; Zbar B; Boffetta P; Brennan P; Rothman N; Chow WH; Waldman FM; Moore LE
Clin Cancer Res; 2008 Aug; 14(15):4726-34. PubMed ID: 18676741
[TBL] [Abstract][Full Text] [Related]
11. Characterization of VHL missense mutations in sporadic clear cell renal cell carcinoma: hotspots, affected binding domains, functional impact on pVHL and therapeutic relevance.
Razafinjatovo C; Bihr S; Mischo A; Vogl U; Schmidinger M; Moch H; Schraml P
BMC Cancer; 2016 Aug; 16():638. PubMed ID: 27530247
[TBL] [Abstract][Full Text] [Related]
12. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
13. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
Shirole NH; Kaelin WG
Hematol Oncol Clin North Am; 2023 Oct; 37(5):809-825. PubMed ID: 37270382
[TBL] [Abstract][Full Text] [Related]
14. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins.
Rohan SM; Xiao Y; Liang Y; Dudas ME; Al-Ahmadie HA; Fine SW; Gopalan A; Reuter VE; Rosenblum MK; Russo P; Tickoo SK
Mod Pathol; 2011 Sep; 24(9):1207-20. PubMed ID: 21602815
[TBL] [Abstract][Full Text] [Related]
15. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
16. Unique molecular alteration patterns in von Hippel-Lindau (VHL) gene in a cohort of sporadic renal cell carcinoma patients from Pakistan.
Khaliq S; Ajaz S; Firasat S; Shahid S; Hasan AS; Sultan G; Mohsin R; Hashmi A; Mubarak M; Naqvi SA; Rizvi SA; Mehdi SQ; Abid A
Mutat Res; 2014; 763-764():45-52. PubMed ID: 24727139
[TBL] [Abstract][Full Text] [Related]
17. VHL genetic alteration in CCRCC does not determine de-regulation of HIF, CAIX, hnRNP A2/B1 and osteopontin.
Nyhan MJ; El Mashad SM; O'Donovan TR; Ahmad S; Collins C; Sweeney P; Rogers E; O'Sullivan GC; McKenna SL
Cell Oncol (Dordr); 2011 Jun; 34(3):225-34. PubMed ID: 21547579
[TBL] [Abstract][Full Text] [Related]
18. VHL and HIF-1α: gene variations and prognosis in early-stage clear cell renal cell carcinoma.
Lessi F; Mazzanti CM; Tomei S; Di Cristofano C; Minervini A; Menicagli M; Apollo A; Masieri L; Collecchi P; Minervini R; Carini M; Bevilacqua G
Med Oncol; 2014 Mar; 31(3):840. PubMed ID: 24446253
[TBL] [Abstract][Full Text] [Related]
19. Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma.
Ordóñez-Navadijo Á; Fuertes-Yebra E; Acosta-Iborra B; Balsa E; Elorza A; Aragonés J; Landazuri MO
Oncogene; 2016 Feb; 35(5):587-94. PubMed ID: 25915846
[TBL] [Abstract][Full Text] [Related]
20. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
He Z; Liu S; Guo M; Mao J; Hughson MD
Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
